Haemoglobinuria is a condition where the oxygen-carrying protein from red blood cells appears in abnormally high amounts in urine, often turning it dark red or brown. When the body breaks down too many red blood cells too quickly in the bloodstream, the released hemoglobin passes through the kidneys and into the urine, signaling a need for careful medical evaluation and treatment.

Understanding How Treatment Goals Are Set

When doctors approach the treatment of haemoglobinuria, they focus first on understanding what is causing red blood cells to break down inside the blood vessels rather than in their normal locations like the spleen, liver, or bone marrow. This abnormal breakdown, called intravascular hemolysis, releases hemoglobin into the bloodstream, which the kidneys then filter into urine, creating the characteristic dark coloration that often alerts patients and doctors to a problem.^[1]

Treatment strategies depend heavily on identifying the underlying cause. The color change in urine is itself a symptom of other conditions, which means that effective treatment must address the root disease rather than just the visible sign. For some patients, haemoglobinuria may appear suddenly and resolve quickly with supportive care. For others, it signals a chronic condition requiring long-term management and ongoing medical supervision.^[3]

The main goals of treatment include stopping or slowing the destruction of red blood cells, preventing complications like kidney damage or blood clots, managing symptoms such as fatigue and shortness of breath, and improving overall quality of life. Treatment approaches vary from supportive care and symptom management to specialized medications and, in severe cases, procedures like bone marrow transplantation.^[2]

Doctors must also consider the stage and severity of the condition when planning treatment. Mild cases with minimal symptoms may require only monitoring and basic supportive measures. More severe cases, particularly those involving a condition called paroxysmal nocturnal hemoglobinuria (PNH), demand more aggressive intervention to prevent life-threatening complications such as blood clots in major blood vessels or progressive kidney failure.^[8]

Standard Treatment Approaches for Haemoglobinuria

The foundation of treatment depends on the specific cause of haemoglobinuria. When doctors identify the underlying condition, they can tailor therapy accordingly. For many causes, including kidney disease, malaria, burns, or poisoning, treatment focuses on addressing the primary illness while providing support to prevent further red blood cell breakdown and protect vital organs, especially the kidneys.^[3]

One of the most important causes requiring specialized treatment is paroxysmal nocturnal hemoglobinuria, a rare genetic condition where a spontaneous mutation affects proteins on the surface of red blood cells. This mutation makes cells vulnerable to attack by part of the immune system called the complement system. Without proper protective proteins, red blood cells break apart easily, releasing hemoglobin into the bloodstream continuously.^[5]

For paroxysmal nocturnal hemoglobinuria specifically, standard treatment has evolved significantly over recent decades. The mainstay of modern therapy involves medications called complement inhibitors, which block the part of the immune system that attacks red blood cells. Two approved medications in this category are eculizumab (known by the brand name Soliris) and ravulizumab (Ultomiris). Both work by targeting a protein called C5 in the complement system, preventing it from breaking down and stopping the formation of what’s called the terminal attack complex, which destroys red blood cells.^[9]

Eculizumab is given through an intravenous line once every two weeks, while ravulizumab requires infusion only once every eight weeks. Patients typically need to continue this medication indefinitely or until their disease goes into remission. Before starting either medication, patients must receive a vaccine against meningococcal infection, which is administered at least two weeks before the first treatment dose. This precaution is necessary because these drugs suppress part of the immune system, making serious infections more likely.^[14]

Another complement inhibitor, pegcetacoplan (Empaveli), targets a different part of the complement system by inhibiting the C3 protein. This medication is given by intravenous infusion twice weekly. It can be prescribed for patients who are new to treatment or those switching from other complement inhibitors. Some patients may need prophylactic antibiotics, particularly penicillin, to reduce infection risk while taking these medications.^[9]

More recently, an oral medication called iptacopan was approved for treating paroxysmal nocturnal hemoglobinuria. This drug works by inhibiting factor B, a component of the alternative complement pathway. Being taken by mouth rather than requiring infusions makes it more convenient for some patients. It is indicated as monotherapy, meaning it can be used alone without other complement inhibitors.^[9]

For patients who continue to experience significant red blood cell destruction outside of blood vessels (called extravascular hemolysis) despite taking C5 inhibitor therapy, another option called danicopan became available. This selective inhibitor of complement factor D is approved as an add-on therapy to C5 inhibitors like eculizumab or ravulizumab when patients still have clinically significant symptoms despite treatment.^[9]

Supportive treatments play a crucial role alongside specific therapies. Many patients require blood transfusions of warmed packed red blood cells when hemolysis causes severe anemia and symptoms that interfere with daily life. Healthcare providers take special care to warm blood products before transfusion to avoid triggering additional red blood cell breakdown. Some patients may receive washed red blood cell units if standard warmed products don’t provide adequate benefit.^[11]

Nutritional supplements form another important part of standard care. Folic acid, typically given at one milligram daily by mouth, helps support the body’s production of new red blood cells. This vitamin is lost during the hemolytic process and needs regular replacement. Iron supplements may also be necessary for some patients, although doctors monitor iron levels carefully because excessive amounts can cause other health problems. Vitamin B12 supplementation may be recommended when laboratory tests show deficiency.^[11]

A substance called erythropoietin, which is a growth factor that stimulates bone marrow to produce more red blood cells, may be prescribed to boost energy levels and reduce the need for blood transfusions. This helps the body keep up with the ongoing destruction of red blood cells by increasing production of new ones.^[14]

Managing blood clot risk represents another critical aspect of standard treatment. Patients with paroxysmal nocturnal hemoglobinuria face significantly increased risk of dangerous blood clots forming in major blood vessels, particularly in the abdomen. Those who develop acute clots should be started immediately on complement inhibitor therapy if not already taking it, as this reduces the chance of clots expanding or recurring. Standard blood clot management includes emergency treatment with heparin followed by long-term maintenance therapy with oral anticoagulants such as warfarin. In some cases, heparin itself can worsen clotting by activating the complement system, which can be prevented by using medications that inhibit the cyclooxygenase system, such as aspirin, ibuprofen, or sulfinpyrazone.^[9]

For patients with another condition called paroxysmal cold hemoglobinuria, where exposure to cold triggers red blood cell breakdown, the main treatment approach focuses on avoiding cold exposure and providing supportive care. Patients require hospitalization during severe episodes to monitor and treat complications from massive hemolysis, including maintaining heart and lung function and ensuring adequate hydration. Healthcare teams monitor anemia daily with complete blood counts, lactate dehydrogenase levels, and reticulocyte counts. The presence of hemoglobinuria is tracked through routine urine testing.^[11]

When underlying secondary causes contribute to haemoglobinuria, such as viral or bacterial infections, appropriate medical therapy targeting those specific conditions becomes part of the treatment plan. Hydration therapy, making the urine less acidic (called alkalinization), and other measures may become necessary to prevent kidney failure from developing.^[11]

Corticosteroids such as prednisone, typically given at doses of 20 to 40 milligrams per day during episodes of hemolysis, provide modest help by modulating complement activity, though they control it poorly compared to newer targeted therapies. Their use has become less central as better treatments have emerged, though they still play a role in some treatment regimens.^[9]

For patients with severe bone marrow failure accompanying paroxysmal nocturnal hemoglobinuria, when the bone marrow cannot produce enough healthy blood cells, immunosuppressive therapy may be considered. Antithymocyte globulin (ATG) and cyclosporine have been used successfully in treating aplastic anemia, a condition that sometimes occurs alongside haemoglobinuria. These medications suppress the immune system to allow bone marrow recovery.^[9]

Advanced Treatment: Stem Cell Transplantation

The only treatment that can cure paroxysmal nocturnal hemoglobinuria completely is an allogeneic hematopoietic stem cell transplantation, also called bone marrow transplant. This procedure replaces damaged stem cells in the bone marrow with healthy ones from a donor, typically a close relative who provides the best tissue match. The new stem cells travel to the bone marrow where they grow into healthy new blood cells that don’t have the genetic mutation causing the disease.^[13]

However, stem cell transplantation carries significant risks, including severe infection and organ damage. Historical data shows that in studies conducted between 1988 and 2006, the mortality rate related to transplantation was 42 percent at 12 months. More recent advances have improved outcomes, but the procedure remains serious and potentially life-threatening. Because of these considerable challenges and risks, bone marrow transplant is not realistic for most patients.^[12]

Doctors typically reserve this treatment option for the most severe cases of paroxysmal nocturnal hemoglobinuria, particularly those with life-threatening complications. Specific indications for considering transplantation include persistent hemolysis that doesn’t respond adequately to other treatments, recurring life-threatening blood clots, and associated severe bone marrow failure where the marrow cannot produce sufficient blood cells. Patients who develop transformation to leukemia, a blood cancer, are also candidates for transplantation.^[9]

Before the transplant procedure, patients undergo preparatory treatments to ready their body for the new cells. Chemotherapy or radiation therapy destroys the old damaged bone marrow so the new stem cells have space to grow and establish themselves. The stem cells are then infused through a long, thin tube placed in the chest or neck. After infusion, careful monitoring continues for weeks and months to watch for complications like graft-versus-host disease, where the donor cells attack the recipient’s body, or rejection, where the body attacks the donor cells.^[14]

Treatments Being Studied in Clinical Trials

While standard complement inhibitor therapies have transformed outcomes for patients with paroxysmal nocturnal hemoglobinuria over the past 15 to 20 years, improving 10-year survival from 50 percent to more than 75 percent, researchers continue investigating new approaches to address remaining challenges. Despite treatment with C5 inhibitors like eculizumab or ravulizumab, some patients continue experiencing extravascular hemolysis, where red blood cells are destroyed outside the bloodstream, resulting in ongoing anemia, persistent need for blood transfusions, continuing fatigue, and reduced quality of life.^[12]

Clinical trials represent different phases of investigation, each designed to answer specific questions about new treatments. Phase I studies primarily assess safety, determining whether a drug or treatment approach can be used in humans and identifying safe dosage ranges. These early studies typically involve small numbers of participants and focus on understanding how the body processes the drug and what side effects occur.^[23]

Phase II trials evaluate whether a treatment shows promise of effectiveness while continuing to monitor safety. These studies involve more participants than Phase I and often use a case-control design where patients with the disease are compared to healthy individuals or to people with the disease who receive standard treatment. Phase II trials help determine optimal dosing and identify which patients might benefit most from the new approach.^[23]

Phase III clinical trials represent the most rigorous testing phase before a treatment can receive regulatory approval. These are typically randomized controlled trials where participants are assigned randomly to receive either the new treatment or the current standard therapy. Phase III studies involve larger patient populations and focus on proving that the new treatment works better than, or as well as, existing options while maintaining acceptable safety. These trials provide the evidence needed for medications to receive approval from regulatory agencies like the U.S. Food and Drug Administration.^[23]

Phase IV studies occur after a drug has been approved and is available for prescription. These post-marketing surveillance studies track how treatments perform in real-world conditions across diverse patient populations over longer time periods. They help identify rare side effects or long-term complications that might not have appeared in earlier, more controlled study conditions.^[23]

Current research into paroxysmal nocturnal hemoglobinuria focuses on several innovative approaches. Investigators are exploring new complement inhibitors that target different points in the complement cascade beyond C5, hoping to provide more complete protection against both intravascular and extravascular hemolysis. Some experimental therapies aim to inhibit the complement system earlier in its activation sequence, which might prevent red blood cell destruction more effectively than current medications.^[12]

Researchers are also studying combination approaches, where two or more medications targeting different parts of the complement system are used together. The approval of danicopan as an add-on therapy to C5 inhibitors represents one example of this strategy already showing promise. Clinical trials continue evaluating other potential combination regimens that might eliminate residual hemolysis more completely than single agents alone.^[9]

Some trials investigate oral formulations of complement inhibitors, building on the success of iptacopan. Developing effective oral medications rather than intravenous infusions could significantly improve convenience and quality of life for patients requiring lifelong treatment. Researchers measure outcomes in these studies not just by laboratory markers of hemolysis but also by patient-reported outcomes like fatigue levels, ability to work, and overall life satisfaction.^[9]

Gene therapy approaches remain in early research stages for paroxysmal nocturnal hemoglobinuria. Because the condition results from a mutation in the PIGA gene, scientists are exploring whether it might be possible to correct this genetic defect in a patient’s own stem cells. If successful, such an approach could potentially cure the disease without requiring a donor for stem cell transplantation. However, gene therapy for this condition remains experimental and is not yet available outside of research settings.^[5]

Clinical trials for rare diseases like paroxysmal nocturnal hemoglobinuria face unique challenges because of the small number of patients available to participate. This makes international collaboration essential. Studies often enroll patients across multiple countries to gather enough data to draw meaningful conclusions. Patients interested in clinical trial participation should discuss options with their healthcare team, who can help identify appropriate trials and determine eligibility.^[12]

Eligibility for clinical trials varies depending on the study phase and objectives. Generally, participants must have a confirmed diagnosis of the condition being studied, fall within certain age ranges, and meet specific criteria regarding disease severity and previous treatments. Some trials enroll only patients who have never received treatment, while others specifically seek patients who have not responded adequately to standard therapies. Participants in clinical trials receive close monitoring and often have access to new treatments before they become widely available.^[12]

Most Common Treatment Methods

• Complement Inhibitor Therapy
  • Eculizumab (Soliris) given by intravenous infusion once every two weeks, blocks C5 protein to prevent red blood cell destruction
  • Ravulizumab (Ultomiris) administered intravenously once every eight weeks with similar mechanism to eculizumab
  • Pegcetacoplan (Empaveli) targets C3 protein, given twice weekly by IV infusion
  • Iptacopan taken orally, inhibits factor B in the alternative complement pathway
  • Danicopan as add-on therapy to C5 inhibitors for patients with ongoing extravascular hemolysis
  • Patients require meningococcal vaccination at least two weeks before starting treatment
• Supportive Care and Symptom Management
  • Blood transfusions using warmed packed red blood cells for severe anemia and symptomatic relief
  • Folic acid supplementation at one milligram daily to support red blood cell production
  • Iron and vitamin B12 supplements when deficiencies are identified
  • Erythropoietin to stimulate bone marrow production of red blood cells
  • Hydration therapy and urine alkalinization to protect kidneys
• Blood Clot Prevention and Treatment
  • Emergency heparin therapy for acute thrombosis
  • Long-term oral anticoagulants such as warfarin
  • Cyclooxygenase inhibitors like aspirin or ibuprofen when heparin worsens clotting
  • Immediate initiation of complement inhibitors when clots develop
• Immunosuppressive Therapy
  • Antithymocyte globulin (ATG) for patients with severe bone marrow failure
  • Cyclosporine to suppress immune system and allow marrow recovery
  • Corticosteroids such as prednisone at 20-40 mg daily during hemolysis episodes
• Bone Marrow Transplantation
  • Allogeneic hematopoietic stem cell transplantation as the only curative option
  • Reserved for severe cases with life-threatening complications or bone marrow failure
  • Requires preparatory chemotherapy or radiation before stem cell infusion
  • Donor typically a close relative with best tissue match
• Preventive Measures
  • Avoiding cold exposure for patients with paroxysmal cold hemoglobinuria
  • Prophylactic antibiotics, particularly penicillin, during complement inhibitor therapy
  • Wearing masks and gloves during travel to prevent infections
  • Regular monitoring of blood counts and kidney function